Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 12.27B
-0.32%-1.72%+37.83%+148.79% 1,007B
-2.16%+1.51%+50.01%+43.93% 567B
-2.70%-0.66%+15.97%+63.07% 392B
-0.29%+1.05%+20.91%+18.37% 328B
-0.37%+1.13%+24.23%+31.91% 277B
+0.58%-2.70%+22.61%+12.52% 275B
-0.44%+5.73%-42.79%-48.37% 196B
-1.31%+1.39%+18.74%+53.45% 189B
-1.03%-2.97%+13.02%+57.34% 154B
Average -0.22%+0.33%+17.84%+42.33% 376.23B
Weighted average by Cap. +0.04%-0.03%+26.48%+67.11%
Logo Galenica
Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!